Inhibition of oncogenic MAPK signaling in combination with neutralizing the anti-apoptotic BCL-2 repertoire leads to the killing of cancer cells. Here, human melanoma cells are treated with PLX-4032 (BRAF V600E inhibitor) and ABT-263 (BCL-2 antagonist) to promote apoptosis (yellow). PMIDs: 24608435, 23152056, and 22268005

Our current research interests are divided into three areas, but adopt a unified theme to decipher the interplay between mitochondria and cell death signaling:

My laboratory’s long-term¬†goals are to provide: 1) Mechanistic insights of how mitochondrial composition and shape impact on cellular metabolism and commitment to apoptosis, 2) explore how cancer-promoting pathways converge on the mitochondrial function to regulate malignancy and chemotherapeutic success, and 3) to reveal novel contributions of the mitochondrial network in tissue homeostasis.

The laboratory is a highly collaborative group on the Mount Sinai campus, which has enriched our scientific impact and experimental skill set — along with creating an ideal atmosphere for mentoring students and post-doctoral fellows.